JAMA Research at Critical Care Reviews 2024 (CCR Down Under)
Dec 11, 2024
auto_awesome
Derek Angus, Chair of Critical Care Medicine at UPMC, joins the discussion alongside JAMA Editor in Chief Kirsten Bibbins-Domingo. They delve into four pivotal critical care trials recently presented in Melbourne. Topics include the effectiveness of sepsis alert systems that significantly lower hospital mortality, evolving oxygen strategies, and the comparison of high-flow nasal oxygen against non-invasive ventilation. They also explore the impact of biomarker-guided protocols in reducing unnecessary antibiotic use among sepsis patients, emphasizing personalized patient care.
The effectiveness of electronic sepsis alerts in reducing in-hospital mortality was confirmed, but their practical implementation remains challenging.
The ADAPT-Sepsis trial highlighted procalcitonin's role in safely shortening antibiotic duration for suspected sepsis patients, improving antibiotic stewardship.
Deep dives
Impact of Electronic Sepsis Alerts
The study on electronic sepsis alerts aimed to assess their effectiveness in reducing in-hospital mortality. Conducted as a large-scale randomized trial, it involved over 60,000 patients across multiple hospitals. The trial demonstrated a significant improvement in hospital mortality when the alerts were activated, with a risk ratio of 0.85. While this indicates the alerts can enhance patient care, questions remain about their operational impact and efficiency in clinical practice.
Oxygen Strategies in Trauma Patients
The Traumox-2 trial investigated the effects of restrictive versus liberal oxygen strategies in trauma patients. Results from the study showed no significant difference in death or respiratory complications between the two approaches over an eight-hour assessment. This neutral finding highlights the need for more personalized oxygen administration strategies, as existing guidelines do not specify optimal oxygen levels for severely injured patients. Further trials are anticipated to refine these strategies in real-world settings.
Biomarker-Guided Antibiotic Stewardship in Sepsis
The ADAPT-Sepsis trial explored the role of biomarkers in guiding the duration of antibiotic treatment for suspected sepsis patients. It compared procalcitonin and C-reactive protein to standard clinical practices for reducing antibiotic use without increasing mortality risk. Findings indicated that the procalcitonin-guided approach effectively shortened antibiotic duration by approximately one day and did so safely. In contrast, the CRP approach did not yield similar reductions, suggesting procalcitonin's potential as a crucial tool in antibiotic stewardship.
JAMA Senior Editor Derek Angus, MD, MPH, and JAMA Associate Editor Christopher Seymour, MD, MSc, discuss 4 critical care trials published in JAMA and simultaneously presented at the 2024 CCR Down Under meeting in Melbourne, Australia, with JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS. Related Content: